Pedro Jesús Gómez-Arias

Dec 18, 2023 | onlinelibrary.wiley.com | Emma Guttman-Yassky |Paola Facheris |Pedro Jesús Gómez-Arias |Ester Del Duca

1 BACKGROUND Atopic dermatitis (AD) is a chronic inflammatory skin disease with complex pathophysiology,1 characterized by skin barrier dysfunction, innate immune system activation, and T-helper 2 (Th2)- and Th22-driven inflammation.2 Th1 and Th17 activation in AD may also play a role alongside Th2/Th22 inflammation and varies by patient race and age.3 Oral abrocitinib is approved for the treatment of moderate-to-severe AD.4 Abrocitinib 200 mg or 100 mg once daily (QD) demonstrated greater...